Hunan Jiudian Pharmaceutical Co Ltd Market Cap ($769.42 Million)
Market Cap & Net Worth: Hunan Jiudian Pharmaceutical Co Ltd (300705)
Hunan Jiudian Pharmaceutical Co Ltd market cap. Hunan Jiudian Pharmaceutical Co Ltd (SHE:300705) has a market capitalization of $769.42 Million (CN¥5.26 Billion) as of November 5, 2026. Listed on the SHE stock exchange, this China-based company holds position #9782 globally and #2487 in its home market, demonstrating a 1.74% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Hunan Jiudian Pharmaceutical Co Ltd's stock price CN¥10.51 by its total outstanding shares 500291194 (500.29 Million). Also see cash flow conversion of Hunan Jiudian Pharmaceutical Co Ltd for how efficiently the company converts equity into cash flow.
Hunan Jiudian Pharmaceutical Co Ltd Market Cap History (2017–2026)
Hunan Jiudian Pharmaceutical Co Ltd market cap history from 2017 to 2026. Data shows growth from $465.11 Million to $769.42 Million (12.43% CAGR). Check Hunan Jiudian Pharmaceutical Co Ltd stock quote for real-time trading data and today's change.
Hunan Jiudian Pharmaceutical Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Hunan Jiudian Pharmaceutical Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore Hunan Jiudian Pharmaceutical Co Ltd annual equity growth to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
0.35x
Hunan Jiudian Pharmaceutical Co Ltd's market cap is 0.35 times its annual revenue
Latest Price to Earnings (P/E) Ratio
2.32x
Hunan Jiudian Pharmaceutical Co Ltd's market cap is 2.32 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $465.11 Million | $534.52 Million | $68.57 Million | 0.87x | 6.78x |
| 2018 | $418.33 Million | $801.38 Million | $71.99 Million | 0.52x | 5.81x |
| 2019 | $440.01 Million | $924.06 Million | $55.07 Million | 0.48x | 7.99x |
| 2020 | $962.67 Million | $978.16 Million | $82.26 Million | 0.98x | 11.70x |
| 2021 | $1.26 Billion | $1.63 Billion | $204.25 Million | 0.78x | 6.19x |
| 2022 | $1.24 Billion | $2.33 Billion | $269.70 Million | 0.53x | 4.61x |
| 2023 | $1.72 Billion | $2.69 Billion | $368.26 Million | 0.64x | 4.66x |
| 2024 | $1.31 Billion | $2.93 Billion | $512.38 Million | 0.45x | 2.56x |
| 2025 | $1.10 Billion | $3.11 Billion | $472.82 Million | 0.35x | 2.32x |
Competitor Companies of 300705 by Market Capitalization
Companies near Hunan Jiudian Pharmaceutical Co Ltd in the global market cap rankings as of November 5, 2026. Also see Hunan Jiudian Pharmaceutical Co Ltd total assets for a full breakdown of the balance sheet.
Key companies related to Hunan Jiudian Pharmaceutical Co Ltd by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #514 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #538 globally with a market cap of $50.42 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #588 globally with a market cap of $45.79 Billion USD ( CN¥312.89 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #621 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #514 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #538 | GALDERMA GROUP AG | NYSE:GALDY | $50.42 Billion | $47.80 |
| #588 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $45.79 Billion | CN¥49.05 |
| #621 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €18.50 |
Market Capitalization of Hunan Jiudian Pharmaceutical Co Ltd (2017–2026)
Market capitalization of Hunan Jiudian Pharmaceutical Co Ltd from 2017 to today. Between 2017 and today, Hunan Jiudian Pharmaceutical Co Ltd's market cap moved from $465.11 Million to $ 769.42 Million, with a yearly change of 12.43%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥769.42 Million | -29.84% |
| 2025 | CN¥1.10 Billion | -16.55% |
| 2024 | CN¥1.31 Billion | -23.41% |
| 2023 | CN¥1.72 Billion | +38.04% |
| 2022 | CN¥1.24 Billion | -1.67% |
| 2021 | CN¥1.26 Billion | +31.30% |
| 2020 | CN¥962.67 Million | +118.78% |
| 2019 | CN¥440.01 Million | +5.18% |
| 2018 | CN¥418.33 Million | -10.06% |
| 2017 | CN¥465.11 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 5th, 2026 the market cap of Hunan Jiudian Pharmaceutical Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $769.42 Million USD |
| MoneyControl | $769.42 Million USD |
| MarketWatch | $769.42 Million USD |
| marketcap.company | $769.42 Million USD |
| Reuters | $769.42 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Hunan Jiudian Pharmaceutical Co Ltd
Hunan Jiudian Pharmaceutical Co., Ltd. researches, develops, produces, and sells pharmaceutical products in China and internationally. The company offers chemical drug preparations, active pharmaceutical ingredients (APIs), pharmaceutical excipients, traditional Chinese medicine, health foods, and rehabilitation and wellness products. Its products portfolio includes loxoprofen sodium gel patches,… Read more